You are here: Industry Insights > uniQure

News List

Who's the next Big Pharma takeout target? Biogen, uniQure, AZ top the list fiercepharma
June 28, 2019
Investors were none too pleased with AbbVie’s planned $63 billion buyout of Allergan, which they made clear by shaving $18 billion off the acquirer’s market cap by the end of the day Tuesday.
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease firstwordpharma
April 10, 2019
The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs to treat serious ……
uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) biospectrumasia
October 17, 2018
Press Release AMT-060 uniQure Haemophilia Clinical Research (R&D) Medical Affairs ESGCT
uniQure starts dosing in pre-pivotal hemophilia B gene therapy trial fiercebiotech
August 27, 2018
Dutch biotech uniQure has treated the first of around three patients due to enroll in its phase 2b dose-confirmation trial of hemophilia B gene therapy AMT-061.
Achillion lures Zelenkofske from uniQure to fill CMO seat fiercebiotech
August 22, 2018
Steven Zelenkofske (uniQure)
UniQure, chasing Spark-level FIX activity, tweaks hemophilia B gene therapy ahead of 2018 pivotal tr fiercebiotech
October 20, 2017
UniQure has modified its hemophilia B gene therapy to dial up factor IX (FIX) activity to the levels achieved by Spark Therapeutics’ rival product.
Meyer leaves troubled uniQure for R&D post at Therachon fiercepharma
August 30, 2017
Meyer had been at the biotech for four years, but uniQure has been hit by commercial flops and major R&D shakeups